Inclusion Criteria:

• * Patients must have histologically confirmed squamous cell carcinoma of the head and neck region planned for definitive or adjuvant treatment with concurrent radiation therapy and systemic therapy
• * Patients may receive platinum-based chemotherapy or cetuximab concurrently with radiation therapy
• * Age \>18 years and ECOG performance status \<2 (Karnofsky \>60).
• * Patients must be willing to use medically certified cannabis as directed after study enrollment
• * Patients must be able to read English, Spanish, or French fluently
• * Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• * Prior diagnosis of cannabis use disorder as defined in the DSM-V
• * Current opioid use disorder on maintenance opioid therapy
• * Current active use of smoked cannabis or cannabis derivatives AND unwillingness to cease use of non-medically certified cannabis for the duration of study participation.
• * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cannabis derivatives
• * Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.